Deucravacitinib in Plaque Psoriasis: Maintenance of Response Over 3 Years in the Phase 3 POETYK PSO-1 and PSO-2 Trials. J of Skin 2023, 7 (6), s241. https://doi.org/10.25251/skin.7.supp.241.